Shares of Entest BioMedical Inc. (PINK: ENTB), a biotechnology company engaged in the development of stem cell therapy treatments for chronic obstructive pulmonary disease, are continuing to climb in early trading today.
At last check, ENTB shares were trading 15.56% higher at $0.0260 on volume of 6.25 million. The stock has gained more than 90% in the last three trading sessions.
Entest BioMedical earlier this month said in a 8K filing that it entered into an Equity Purchase Agreement with Southridge Partners II LP.
As per the terms of the Equity Purchase Agreement, Southridge will buy, at ENTB’s election, up to $10 million of ENTB’s registered common stock. ENTB can deliver a put notice to Southridge at any time.
Recent Comments